Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nanco Hefting

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of Market Access & Health Policy|March 27, 2026
Addressing Unmet Medical Needs in Drug Development: Assessment and Implications for Regulatory and Clinical Development StrategiesCarla Domingo-Esteban, Inka Heikkinen, Nanco Hefting
International Journal of Geriatric Psychiatry|July 25, 2018
Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability studyUlla Lepola, Nanco Hefting, Doris Zhang, et al.
The Journal of Clinical Psychiatry|February 26, 2025
Brexpiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder: A Full-Factorial Randomized Clinical TrialMary Hobart, Denise Chang, Nanco Hefting, et al.
Acta Neuropsychiatrica|September 19, 2018
A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorderMichael Bauer, Nanco Hefting, Annika Lindsten, et al.
JAACAP Open|June 16, 2025
Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label StudySarah D Atkinson, Alpesh Shah, Maria Victoria Burgess, et al.
Therapeutic Innovation & Regulatory Science|May 27, 2023
Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric DisorderElena Polverejan, Michael O'Kelly, Nanco Hefting, et al.
Schizophrenia Bulletin Open|December 13, 2021
Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: <i>Post Hoc</i> Analysis of Short- and Long-Term StudiesStephen R Marder, Stine R Meehan, Catherine Weiss, et al.
Journal of Psychopharmacology (Oxford, England)|March 11, 2021
Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar maniaEduard Vieta, Gary Sachs, Denise Chang, et al.
Frontiers in Neurology|August 7, 2024
Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer's dementiaJuliette Meunier, Kristin Creel, Angély Loubert, et al.
Journal of Clinical Psychopharmacology|April 5, 2019
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive DisorderMary Hobart, Peter Zhang, Aleksandar Skuban, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of Market Access & Health Policy|March 27, 2026
Addressing Unmet Medical Needs in Drug Development: Assessment and Implications for Regulatory and Clinical Development StrategiesCarla Domingo-Esteban, Inka Heikkinen, Nanco Hefting
International Journal of Geriatric Psychiatry|July 25, 2018
Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability studyUlla Lepola, Nanco Hefting, Doris Zhang, et al.
The Journal of Clinical Psychiatry|February 26, 2025
Brexpiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder: A Full-Factorial Randomized Clinical TrialMary Hobart, Denise Chang, Nanco Hefting, et al.
Acta Neuropsychiatrica|September 19, 2018
A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorderMichael Bauer, Nanco Hefting, Annika Lindsten, et al.
JAACAP Open|June 16, 2025
Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label StudySarah D Atkinson, Alpesh Shah, Maria Victoria Burgess, et al.
Therapeutic Innovation & Regulatory Science|May 27, 2023
Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric DisorderElena Polverejan, Michael O'Kelly, Nanco Hefting, et al.
Schizophrenia Bulletin Open|December 13, 2021
Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: <i>Post Hoc</i> Analysis of Short- and Long-Term StudiesStephen R Marder, Stine R Meehan, Catherine Weiss, et al.
Journal of Psychopharmacology (Oxford, England)|March 11, 2021
Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar maniaEduard Vieta, Gary Sachs, Denise Chang, et al.
Frontiers in Neurology|August 7, 2024
Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer's dementiaJuliette Meunier, Kristin Creel, Angély Loubert, et al.
Journal of Clinical Psychopharmacology|April 5, 2019
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive DisorderMary Hobart, Peter Zhang, Aleksandar Skuban, et al.
Pageof 3